The core pathology of coronavirus disease 2019 (COVID-19) is infection of airway cells by
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that results in excessive …

Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence
of antiphospholipid antibodies, such as lupus anticoagulant, anticardiolipin antibodies and …

Rivaroxaban is an effective and safe alternative to warfarin in patients with atrial fibrillation
and venous thromboembolism. We tested the efficacy and safety of rivaroxaban compared …

Background High incidence of thrombosis in COVID‐19 patients indicates a
hypercoagulable state. Hence, exploring the involvement of antiphospholipid antibodies …

Antiphospholipid Syndrome Antiphospholipid antibodies can induce endothelial-cell,
complement, platelet, neutrophil, and monocyte activation, leading to thrombosis, renal …

Background: The potential role of new oral anticoagulants in antiphospholipid antibody
syndrome (APS) remains uncertain. Objective: To determine whether rivaroxaban is …

Portal vein thrombosis unrelated to solid malignancy is common in patients with cirrhosis,
but less frequently observed in patients without cirrhosis. Prompt diagnosis and …

Antiphospholipid syndrome (APS) is a thrombo-inflammatory disease propelled by
circulating autoantibodies that recognize cell surface phospholipids and phospholipid …

Background Rivaroxaban is established for the treatment and secondary prevention of
venous thromboembolism, but whether it is useful in patients with antiphospholipid …

Currently, we use the classification criteria for antiphospholipid syndrome (APS) formulated
during the consensus conference in Sapporo and revised in Sydney 1. Classification criteria …